1. Scrip
  2. >>Business

Consumer Spin-Off Finally Achieved, GSK Will Weigh More M&A

Could Have £12bn To Spend On M&A

 
• By Andrew McConaghie

GSK is entering a new era, and CEO Emma Walmsley looks likely to use new finances for more targeted M&A.

GSK HQ
The spin-off is the biggest restructure in 20 years for the company, which will now focus on pharma and vaccines. • Source: Shutterstock

The long-awaited spin-off of Haleon from GSK has arrived, creating new standalone market leader in consumer health, and leaving behind a leaner pharma and vaccines company hoping to reclaim its place as a sector leader.

Haleon, purveyor of brands such as Sensodyne toothpaste and Advil painkillers, began trading on the London Stock Exchange on 18...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

AI Is Inevitable, But Useful Only If Solves The Right Problems

 
• By Mandy Jackson

Scrip spoke with executives at artificial intelligence biotech firms and a big pharma company during the recent BIO conference about using AI in ways that add real value to drug development.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 
• By Alaric DeArment

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.